In patients with HER2-positive MBC, the prognostic value of stromal tumor infiltrating lymphocytes (sTILs) showed conflicting results in retrospective analyses of several studies and a retrospective series of patients mainly evaluating sTILs in quantitative manner [15–18]. The gene discussed is ERBB2; the disease is neoplasm.